SWOG S1826: Frontline N-AVD vs BV-AVD in Advanced Hodgkin’s Lymphoma

The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia or myelodysplastic syndromes has been approved by the FDA.

The CELESTIAL-301 trial evaluating SynKIR-310, a novel CAR T-cell therapy, has dosed its first patient with relapsed/refractory B-cell non-Hodgkin lymphoma.

Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.

Axatilimab has gained FDA approval in 9 mg and 22 mg vials, expanding treatment options for patients with chronic GVHD after 2 prior therapy failures.

Enrollment in the LOTIS-5 trial of loncastuximab tesirine-lpyl with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma has been completed.

The phase 3 ARES study of MaaT013 in patients with acute GVHD with gastrointestinal involvement met its primary end point of overall response rate at day 28.